360 related articles for article (PubMed ID: 33008789)
1. Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences.
Tural D; Ölmez ÖF; Sümbül AT; Artaç M; Özhan N; Akar E; Çakar B; Köstek O; Ekenel M; Erman M; Coşkun HŞ; Selçukbiricik F; Keskin Ö; Türköz FP; Oruç K; Bayram S; Yılmaz U; Bilgetekin İ; Yıldız B; Şendur MAN; Paksoy N; Dirican A; Erdem D; Selam M; Tanrıverdi Ö; Paydaş S; Urakçı Z; Atağ E; Güncan S; Ürün Y; Alkan A; Kaya AO; Özyükseler DT; Taşkaynatan H; Yıldırım M; Sönmez M; Başoğlu T; Gündüz Ş; Kılıçkap S
Eur Urol Focus; 2021 Sep; 7(5):1061-1066. PubMed ID: 33008789
[TBL] [Abstract][Full Text] [Related]
2. Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
Sternberg CN; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Banna GL; De Giorgi U; Masini C; Bamias A; Garcia Del Muro X; Duran I; Powles T; Gamulin M; Zengerling F; Geczi L; Gedye C; de Ducla S; Fear S; Merseburger AS
Eur Urol; 2019 Jul; 76(1):73-81. PubMed ID: 30910346
[TBL] [Abstract][Full Text] [Related]
3. Response to first-line chemotherapy regimen is associated with efficacy of ımmune checkpoint blockade therapies in patients with metastatic urothelial carcinoma.
Tural D; Selçukbiricik F; Ölmez ÖF; Sümbül AT; Erman M; Coşkun HŞ; Artaç M; Kılıçkap S
Int J Clin Oncol; 2022 Mar; 27(3):585-591. PubMed ID: 34762201
[TBL] [Abstract][Full Text] [Related]
4. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States.
Pal SK; Hoffman-Censits J; Zheng H; Kaiser C; Tayama D; Bellmunt J
Eur Urol; 2018 May; 73(5):800-806. PubMed ID: 29478735
[TBL] [Abstract][Full Text] [Related]
5. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.
Ning YM; Suzman D; Maher VE; Zhang L; Tang S; Ricks T; Palmby T; Fu W; Liu Q; Goldberg KB; Kim G; Pazdur R
Oncologist; 2017 Jun; 22(6):743-749. PubMed ID: 28424325
[TBL] [Abstract][Full Text] [Related]
6. Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma).
Drakaki A; Powles T; Bamias A; Martin-Liberal J; Shin SJ; Friedlander T; Tosi D; Park C; Gomez-Roca C; Joly Lobbedez F; Castellano D; Morales-Barrera R; Moreno-Candilejo I; Fléchon A; Yuen K; Rishipathak D; DuPree K; Young F; Michielin F; Shemesh CS; Steinberg EE; Williams P; Lee JL
Clin Cancer Res; 2023 Nov; 29(21):4373-4384. PubMed ID: 37651261
[TBL] [Abstract][Full Text] [Related]
7. Swiss experience of atezolizumab for platinum-pretreated urinary tract carcinoma: the SAUL study in real-world practice.
Cathomas R; Schardt J; Pless M; Llado A; Mach N; Riklin C; Haefeli J; Fear S; Stenner F
Swiss Med Wkly; 2020 May; 150():w20223. PubMed ID: 32399958
[TBL] [Abstract][Full Text] [Related]
8. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
Galsky MD; Arija JÁA; Bamias A; Davis ID; De Santis M; Kikuchi E; Garcia-Del-Muro X; De Giorgi U; Mencinger M; Izumi K; Panni S; Gumus M; Özgüroğlu M; Kalebasty AR; Park SH; Alekseev B; Schutz FA; Li JR; Ye D; Vogelzang NJ; Bernhard S; Tayama D; Mariathasan S; Mecke A; Thåström A; Grande E;
Lancet; 2020 May; 395(10236):1547-1557. PubMed ID: 32416780
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab.
Tural D; Ölmez ÖF; Sümbül AT; Özhan N; Çakar B; Köstek O; Ekenel M; Erman M; Coşkun HŞ; Selçukbiricik F; Keskin Ö; Türköz FP; Oruç K; Bayram S; Bilgetekin İ; Yıldız B; Şendur MAN; Paksoy N; Dirican A; Erdem D; Selam M; Tanrıverdi Ö; Paydaş S; Urakçı Z; Atağ E; Güncan S; Ürün Y; Alkan A; Kaya AO; Özyükseler DT; Taşkaynatan H; Yıldırım M; Sönmez M; Başoğlu T; Gündüz Ş; Kılıçkap S; Artaç M
Int J Clin Oncol; 2021 Aug; 26(8):1506-1513. PubMed ID: 34023933
[TBL] [Abstract][Full Text] [Related]
10. Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial.
van der Heijden MS; Loriot Y; Durán I; Ravaud A; Retz M; Vogelzang NJ; Nelson B; Wang J; Shen X; Powles T
Eur Urol; 2021 Jul; 80(1):7-11. PubMed ID: 33902955
[TBL] [Abstract][Full Text] [Related]
11. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens.
Perez-Gracia JL; Loriot Y; Rosenberg JE; Powles T; Necchi A; Hussain SA; Morales-Barrera R; Retz MM; Niegisch G; Durán I; Théodore C; Grande E; Shen X; Wang J; Nelson B; Derleth CL; van der Heijden MS
Eur Urol; 2018 Mar; 73(3):462-468. PubMed ID: 29273410
[TBL] [Abstract][Full Text] [Related]
12. Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study.
Petrylak DP; Powles T; Bellmunt J; Braiteh F; Loriot Y; Morales-Barrera R; Burris HA; Kim JW; Ding B; Kaiser C; Fassò M; O'Hear C; Vogelzang NJ
JAMA Oncol; 2018 Apr; 4(4):537-544. PubMed ID: 29423515
[TBL] [Abstract][Full Text] [Related]
13. Real-world data of atezolizumab in patients with previously treated locally advanced or metastatic urothelial bladder cancer.
Díaz Acedo R; Galvan Banqueri M; Artacho Criado S; Fernández Parra EM; Jiménez Galán R; Gago Sánchez AI; Marín Pozo JF; Martínez Bautista MJ
Int J Clin Pharm; 2024 Apr; 46(2):382-389. PubMed ID: 38112892
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J
Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625
[TBL] [Abstract][Full Text] [Related]
15. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.
Patel MR; Ellerton J; Infante JR; Agrawal M; Gordon M; Aljumaily R; Britten CD; Dirix L; Lee KW; Taylor M; Schöffski P; Wang D; Ravaud A; Gelb AB; Xiong J; Rosen G; Gulley JL; Apolo AB
Lancet Oncol; 2018 Jan; 19(1):51-64. PubMed ID: 29217288
[TBL] [Abstract][Full Text] [Related]
16. Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration.
Vander Velde N; Guerin A; Ionescu-Ittu R; Shi S; Wu EQ; Lin SW; Hsu LI; Saum KU; de Ducla S; Wang J; Li S; Thåström A; Liu S; Shi L; Leppert JT
Eur Urol Oncol; 2019 Feb; 2(1):12-20. PubMed ID: 30929841
[TBL] [Abstract][Full Text] [Related]
17. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
[TBL] [Abstract][Full Text] [Related]
18. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Powles T; Durán I; van der Heijden MS; Loriot Y; Vogelzang NJ; De Giorgi U; Oudard S; Retz MM; Castellano D; Bamias A; Fléchon A; Gravis G; Hussain S; Takano T; Leng N; Kadel EE; Banchereau R; Hegde PS; Mariathasan S; Cui N; Shen X; Derleth CL; Green MC; Ravaud A
Lancet; 2018 Feb; 391(10122):748-757. PubMed ID: 29268948
[TBL] [Abstract][Full Text] [Related]
19. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Balar AV; Galsky MD; Rosenberg JE; Powles T; Petrylak DP; Bellmunt J; Loriot Y; Necchi A; Hoffman-Censits J; Perez-Gracia JL; Dawson NA; van der Heijden MS; Dreicer R; Srinivas S; Retz MM; Joseph RW; Drakaki A; Vaishampayan UN; Sridhar SS; Quinn DI; Durán I; Shaffer DR; Eigl BJ; Grivas PD; Yu EY; Li S; Kadel EE; Boyd Z; Bourgon R; Hegde PS; Mariathasan S; Thåström A; Abidoye OO; Fine GD; Bajorin DF;
Lancet; 2017 Jan; 389(10064):67-76. PubMed ID: 27939400
[TBL] [Abstract][Full Text] [Related]
20. Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02.
Siefker-Radtke AO; Cho DC; Diab A; Sznol M; Bilen MA; Balar AV; Grignani G; Puente E; Tang L; Chien D; Hoch U; Choudhury A; Yu D; Currie SL; Tagliaferri MA; Zalevsky J; Hurwitz ME; Tannir NM
Eur Urol; 2022 Oct; 82(4):365-373. PubMed ID: 35643589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
